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1 Introduction
1.1 Background
The rapid increase in availability of biomedical data has assisted the development of mathematical models
to understand the behavior of many human diseases. In particular, nonlinear ODEs have been used to model
intra-host dynamics of viral infections such as hepatitis C virus (HCV) and HIV [6, 14, 16, 21]. The use of
such models continues to provide insights into disease pathogenesis as well as optimal treatment strategies.
In general, the term forward problem refers to the process of computing a model’s output given a specific
set of parameters. In the context of ODEs, the forward problem of finding a solution to the model equations
has been well-studied, and a variety of analytical and numerical techniques are available. However, when
modeling biological phenomena such as viral dynamics, one must typically estimate parameter values from
the experimentally measured output variables. This process of inferring model parameters is known as an
inverse problem, which is often formulated in terms of least squares or maximum likelihood. Setting aside
the diculties of the resulting numerical optimization, the solution of inverse problems is still highly non-
trivial. The structure of the model, the quantity and quality of the data, and the timing of the experimental
measurements canmake parameters impossible to estimate accurately. To avoidmaking spurious inferences,
one should address the feasibility of theproblemprior to conductingparameter estimation. Parameterswhich
cannot be accurately estimated should be fixed in the model to reasonable values.
In this paper, we study parameter estimation in a model for HCV using techniques from sensitivity and
identifiability analysis. Sensitivity analysis is used to determine which model parameters most influence the
output. The natural connection to inverse problems is that parameters which are not sensitive may be di-
cult to estimate. Identifiability analysis, on the other hand, addresses the question of whether solutions to
the inverse problem are unique, i.e., whether dierent sets of parameters can provide equally optimal fits.
Literature on identifiability of nonlinear ODEs used to model viral dynamics was recently reviewed by Miao,
Xia, Perelson andWu [13]. Most of this work is in the context of HIV, however, and identifiability of hepatitis C
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models is less examined [10, 20]. Baker, Bocharov, Paul and Rihan [3] also give a general discussion of sensi-
tivity, identifiability, and parameter selection in similar models without focusing on any particular modeling
setting. This paper addresses a need for the combined study of the sensitivity and identifiability of HCVmodel
parameters.
1.2 Modeling
The first mathematical model of hepatitis C viral dynamics was formulated in 1998 by Neumann, Lam,
Dahari, Gretch,Wiley, Layden and Perelson to study the antiviral eects of interferon-α (IFN) [14]. Themodel
is given by
dT
dt = s − dT − (1 − η)βVT,
dI
dt = (1 − η)βVT − δI,
dV
dt = (1 − ϵ)pI − cV,
where the state variables T and I denote concentrations of healthy and infectedhepatocytes, andV represents
the concentration of virions in the liver fluid. At the time, it was unknown whether IFN acted by inhibiting
infection of healthy cells or by reducing virion production in infected cells. In the model, these two mech-
anisms correspond to η > 0 and ϵ > 0, respectively. A major contribution of [14] was determining that
interferon acts through the ϵ mechanism rather than the η mechanism, i.e., that IFN acts by inhibiting
the production of virions.
Since these initial modeling eorts, the standard of care for HCV has evolved to include IFN as well as
the antiviral ribavirin, which acts by rendering some virions noninfectious [11]. To study the response of
hepatitis C to this combined treatment, Snoeck et al. [21] proposed several additions to the original Neumann
model. This revised model is as follows:
dT
dt = s + rT(1 − T + ITmax ) − dT − βVIT,
dI
dt = βVIT + rI(1 − T + ITmax ) − δI,
dVI
dt = (1 − ρ̄)(1 − ϵ̄)pI − cVI ,
dVNI
dt = ρ̄(1 − ϵ̄)pI − cVNI .
Note that VI denotes the concentration of infectious virions, and VNI represents the concentration of
noninfectious virions. Also note the addition of terms with coecient r that correspond to the liver’s
regenerative properties. The dynamics of this system after the end of treatment are of interest, so Snoeck
et al. [21] include exponential decay of the drug ecacies ϵ and ρ, which correspond to IFN and ribavirin.
In other words, we have
ϵ̄(t) = ϵe−k(t−tend)+
and
ρ̄(t) = ρe−k(t−tend)+ ,
where tend marks the end of treatment, and(a)+ = {{{a if a ≥ 0,0 otherwise.
One final feature of the model is that virion production is “switched o” – that is, terms involving p are
eliminated – while the concentration of infected cells is lower than 1 per 13.5 × 103 mL, as this implies there
is less than one such cell in the entire liver.
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Parameter Interpretation Typical value
R0 basic reproduction number 7.15
β infection rate 8.7 × 10−9 mLvirion⋅day
δ infected cell death rate 0.139 per day
p virion production rate 25.1 virionshepatocyte⋅day
c virion elimination rate 4.53 per day
r cell proliferation rate 5.62×10−3 per day
ϵ peginterferon ecacy 89.6%
ρ ribavirin ecacy 40–60%
k ecacy decay rate 0.0238 per day
s cell production rate 6.17 × 104 hepatocytesmL⋅day
Tmax total number of cells per mL 1.85 × 107 hepatocytesmL
d cell death rate 0.003 per day
Table 1.Model parameters and typical values estimated in [21].
A full listing of parameters with typical values estimated by Snoeck et al. [21] is given in Table 1. The
parameters s, Tmax, and d are considered known. Note that β was not estimated in [21] but is computed
using the relation
R0 = pβscδd ,
where R0 is the so-called basic reproduction number of the infection. Also, we use the estimated value for δ
corresponding to patientswith the G1 variant of the virus (slightlymore common in theUnited States, accord-
ing to [21]). Finally, the ecacy parameters ϵ and ρ given in the table correspond to interferon and ribavirin
doses of 180μ g/week and 1, 000/1, 200mg/day, respectively.
The Snoeck model poses several challenges to parameter estimation. The viral load,
V = VNI + VI ,
is the only function of the state variables typically observed in a clinical setting. Additionally, the viral load is
measurable only to aminimum value of around 50 international units/mL [21]. Thus, the available viral load
data are left-censored, as shown by Figure 1. As we will discuss, the presence of censored data negatively
impacts identifiability and also complicates maximum likelihood parameter estimation.
2 Methods
2.1 Parameter estimation
A common method for conducting parameter estimation in ODE models is minimization of an ordinary least
squares cost function [4]. Suppose q is a vector containing the estimated parameters in the Snoeck model.
We define a cost function
J(q) = N∑
k=1[log10 Vmodel(tk;q) − log10 Vmeasured(tk)]2,
where Vmeasured(tj) is the experimentally measured viral load at the jth time point, and Vmodel is the model
output. The parameter estimation problem is then to compute the uniqueminimizer of J, if it exists. Note that
uniqueness of the minimizing parameter vector is an issue addressed by identifiability analysis.
The initial conditions for our system are not known a priori and are dicult to measure in a clinical
setting. Thus, we follow the methodology of Ransley [19], who also worked with the Snoeck model, and take
initial conditions equal to the infected steady state of the model, which depends on the parameters.
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Figure 1. (a) Viral load data from a cured patient. (b) Data from a patient who relapses after treatment ends.
Assuming the data are uncensored and produced by the model with additive and independent Gaussian
noise, the ordinary least squares estimate is also themaximum likelihood estimate.However, in our case there
is censoring in the data, and least squares does not suce as a statistically rigorousmethodology. Instead we
compute maximum likelihood parameter estimates using an expectation maximization (EM) algorithm [8].
Details regarding the use of this algorithm with ODE models can be found in [1, 2].
To accompany the parameter estimates, we compute the usual asymptotic confidence intervals [4].
Suppose we are estimating a parameter vector q ∈ ℝM with the least squares solution q̂. Assuming Gaussian
errors with variance σ2 and a large sample size N, the sampling variance of the least squares estimate q̂j is
s2j = Var(q̂j) ≈ σ2((STS)−1)jj ,
where (S)ij = ∂ log10 Vmodel∂qj (ti;q)
is the sensitivity matrix (described below). Since s2j is unknown, we use the estimate ̂s2j obtained by plugging
in q̂ and σ̂2 for the true values. We use a standard estimate,
σ̂2 = 1N −M J(q̂),
for the variance parameter. An approximate 95% confidence interval for qj is then q̂j ± τN−M.975 ̂sj, where τN−M.975
denotes the .975 quantile of a Student’s t-distributionwithN −M degrees of freedom.Note that the theory for
these confidence intervals does not hold in the censored data setting; thus, we only give confidence intervals
when the viral load data is well above the censoring level.
2.2 Sensitivity analysis
When conducting parameter estimation, the relation between parameters and model output is of obvious
importance and can be studied using techniques from sensitivity analysis. In particular, we compute sen-
sitivity functions which quantify the eects of small perturbations in the parameters. These functions are
merely partial derivatives of state or output variables with respect to parameters. For example, in our case
∂V
∂p (t;q∗) is the sensitivity of viral load to the parameter p, evaluated at q∗. Because the sensitivity functions
depend on the nominal value q∗, they are inherently local. Additionally, if at time t the viral load falls below
the censoring level, infinitesimal perturbations to the parameters will have no eect on the observed viral
load. In this case all sensitivities ∂V∂qj (t;q∗) are zero.
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We compute sensitivity functions numerically since analytical solutions to the Snoeck model are not
available. For ease of notation, let
x = [T I VI VNI]T
and let y = VI + VNI be the output. Our model is given by
dx
dt = f(t, x, q),
y = g(x) = x3 + x4.
The desired sensitivity functions are then
∂y
∂q = ∂g∂x ∂x∂q .
Sensitivities can be computed using finite dierence approximations or by solving the system
d
dt
∂x
∂q = ∂f∂x ∂x∂q + ∂f∂q
with
∂x
∂q
儨儨儨儨儨儨t=0 = ∂x0∂q ,
where x0(q) is the vector of parameter-dependent initial conditions. In this work, we apply automatic dier-
entiation to compute ∂f∂x and
∂f
∂q exactly. Automatic dierentiation (AD) is able to compute derivatives directly
from computer source code by applying elementary derivative rules.We use aMATLAB implementation of AD
by Martin Fink and solve the sensitivity ODEs to high precision with a fourth order Runge–Kutta method [9].
As an extreme case, suppose the model output is not sensitive at all to a certain parameter and ∂y∂qj = 0.
The parameter qj will be impossible to estimate because it has no influence on the model output. In practice,
one compares the sensitivities of model parameters relative to one another. It is useful, then, to scale the
output sensitivities and compute dimensionless sensitivity coecients,
Cj(q) = [ 1tf − t0 tf∫
t0
儨儨儨儨儨儨儨 ∂y∂qj qjmaxt y 儨儨儨儨儨儨儨2 dt]1/2.
Parameters with drastically lower sensitivities are less likely to be identifiable from data.
Local sensitivity analysis can be inadequate if the uncertainty in the parameter values is high. Thus,
a global sensitivity analysis may be required. If the patient-specific parameters are assumed to follow some
probability distribution F(q) on the population level, one can in principle compute expected values of the
local sensitivity coecients: 피q(Cj) = ∫
Q
Cj(q) dF(q).
In practice the numerical integration may be intractable due to the high dimensional space of parameters Q.
Hence, we use a Monte Carlo approximation. We generate a sequence of independent parameter values{qk}Bk=1 from the distribution F(q) and approximate the expected value with a sample mean:
Cj = 1B B∑k=1 Cj(qk).
Since each Monte Carlo estimate is just a sample mean, we are guaranteed convergence by the law of large
numbers and can form confidence intervals based on the central limit theorem.
For the global sensitivity analysis in this work, we take the patient-specific parameters to be distributed
log-normally according to the population-based model fit in [21]. Note that only the marginal distributions
are given, so our computations are ignorant of any covariances between parameters. Also, it was observed
that the parameter-dependent initial conditions can have negative components at certain points in the
parameter space. Thus, when drawing parameters from the hypothesized distribution, we keep only param-
eter sets which give non-negative initial conditions.
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2.3 Identifiability
In this work, we use a sensitivity-basedmethod for local identifiability analysis. Many similar approaches are
reviewed in [13]. To motivate this approach, consider as in [13] the first order Taylor expansion
y(t, q) ≈ y(t, q∗) + ∂y(t, q)∂q 儨儨儨儨儨儨q=q∗ (q − q∗),
which approximates the change in model output given a small perturbation ∆q = q − q∗ to the parameters.
Now suppose we have experimental observations ŷ(tk). Substituting the Taylor approximation into the least
squares cost function, we obtain
J(q) ≈ N∑
k=1[ŷ(tk) − y(tk , q∗) − ∂y(tk , q)∂q 儨儨儨儨儨儨q=q∗∆q]2≈ N∑
k=1[∂y(tk , q)∂q 儨儨儨儨儨儨q=q∗∆q]2,
where the second step assumes the residuals rk(q∗) = ŷ − y(tk , q∗) are small and negligible. This approxima-
tion to the cost function can be expressed concisely as
J(q) = (S∆q)TS∆q,
where S is the so-called sensitivity matrix, which is defined by
Sij = ∂y∂qj (ti , q∗).
Note that J(q∗) = 0, which is expected since we took the residuals rk(q∗) to be negligible. Now suppose ∆q is
an eigenvector of STS with STS∆q = λ∆q. Then we have
J(q∗ + ∆q) ≈ ∆qTSTS∆q= ∆qT(λ∆q)= λ‖∆q‖22.
Wesee that if ∆q is an eigenvectorwith eigenvalue λ = 0, then to secondorder approximation J(q∗ + h∆q) = 0.
The least squares cost function does not change values when moving from q∗ to q∗ + h∆q, with h arbitrary.
Thus, the parameters are locally unidentifiable at q∗.
In practice, STS having very small eigenvalues is also a problem for parameter identification. Thus, we
have the following algorithm from Quaiser and Mönnigmann [18]:
(1) Form the matrix F = STS and compute eigenvalues:|λ1| ≤ |λ2| ≤ ⋅ ⋅ ⋅ ≤ |λn|.
(2) If |λ1| is less than some threshold ε, conclude that there is an unidentifiable parameter. (Following [18],
we use ε = 10−4, but in principle the choice of ε ought to depend on measurement error level.)
(3) The largest magnitude component of the eigenvector v1 corresponds to the least identifiable parameter.
Remove the corresponding column from S and repeat from step 1.
An eigenvector v with small corresponding eigenvalue is a direction in the parameter space in which the cost
function is locally flat. Intuitively, by removing the parameter associated with the largest component of v,
i.e., the primary direction of the vector, we avoid this degeneracy.
Note that this algorithm is most appropriate when the parameters q are nondimensional or have compa-
rable scales; otherwise, the directions of the eigenvectors of F are not meaningful. Moreover, recall that our
optimization criterion involves the log viral load, or log(VI + VNI) in the Snoeckmodel. For these reasons, we
use the following scaled sensitivity matrix in our local identifiability analysis:
S̃ij = ∂y∂qj (ti , q∗) q∗jy(ti , q∗) = ∂ log y∂ log qj (ti , q∗),
where y = VI + VNI is the total viral load as before.
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2.4 Subset selection
It is desirable that the parameters estimated from experimental data are both sensitive and identifiable. In
this work, we use a simple algorithm to choose a subset of parameters with these properties:
(1) Begin with the full parameter set Q.
(2) Remove parameters found to be not sensitive during global analysis to obtain QS ⊂ Q.
(3) Conduct local identifiability analysis on parameters in QS to obtain an identifiable parameter set QI .
Since the third step is local,we repeat the procedure atmanypoints in the parameter space. Parameterswhich
appear most often in QI form the final subset. The parameters not in this final subset are fixed to the “typical
values” shown in Table 1.
3 Results
3.1 Model analysis
Global sensitivity analysis was performed on the Snoeck model according to the Monte Carlo approximation
detailed in Section 2.2. A total of 5,000 parameter sets were split into two categories: one for parameter sets
which produce uncensored viral load data and another for parameter sets which produce viral loads that
fall below the censoring level. All simulations were conducted using 48 weeks of treatment and 72 weeks
of observations at 4 week intervals. The averaged sensitivity coecients for the uncensored and censored
cases are illustrated in Figures 2 (a) and 2 (b), respectively, and 95% confidence intervals are included as
error bars.
Sensitivities for the censored data are lower overall, which is expected since sensitivity at censored time
points is considered zero.More importantly, note the sharpbreak inFigure 2 (a) between the sixmost sensitive
parameters and the two least sensitive parameters. This pattern suggests that the insensitive parameters r
and k should not be estimated. A similar pattern of sensitivities is observed in Figure 2 (b), although the
relative sensitivity of ρ is not as clear. Conservatively, we elect not to estimate ρ.
The global sensitivity results were used to conduct subset selection using 500 parameter sets split into
the same two categories. Out of these 500 parameter sets, 408 yielded censored data and the remaining 92
yielded uncensored data. Figure 3 shows the proportions of locally identifiable subsets containing each of the
globally sensitive parameters. In the uncensored data case (Figure 3 (a)), four of the six sensitive parameters
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Figure 2. Averaged sensitivity coecients for (a) patients with uncensored data and (b) patients with censored data.
5,000 total Monte Carlo samples were used.
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Figure 3. Results of subset selection for (a) patients with uncensored data and (b) patients with censored data.
appear in the selected subsets 100% of the time, while p and c seem to be less identifiable. Note that Snoeck
et al. [21], in their population-based model fitting, chose to estimate a single population-wide value for p
but let c vary by patient. Moreover, the inter-patient standard deviation of c was estimated to be 120% of its
typical value, indicating that the correspondingbiological parametermay vary drasticallywithin the sampled
population [21]. For these reasons, we choose to estimate c and fix p to the typical value reported in [21].
The final subset is
Quc = {β, δ, c, ϵ, ρ}.
Subset selection in the censored data case (Figure 3 (b)) is less conclusive. The final subset of parameters
contains those which are identifiable at least 50% of the time:
Qc = {δ, c, ϵ}.
This set is smaller than the one chosen for uncensored data, which is consistent with our expectations.
3.2 Model fitting
After subset selection, the model was fit to two data sets taken from [21]. The first set of data is from a patient
exhibiting partial virologic response (PVR). The patient in the second data set undergoes a relapse after
viral load dips below the censoring level. Since the data are censored, expectationmaximization was used to
obtain a maximum likelihood estimate of the parameters. The data and model fit are shown in Figure 4, and
the optimized parameters are listed in Table 2. We reiterate that only the parameters chosen by the subset
selection are estimated, and the rest are fixed to ‘typical values’ found in [21]. Notice that the data shown
in Figure 4 (a) comes from a patient undergoing 32 weeks of treatment, while we performed subset selection
under the assumption of a 48week treatment period. Dierent treatment times will aect parameter sensitiv-
ities, which are the main factors in our subset selection method. In this case, however, subset selection with
a 32 week treatment period yielded the exact same results in the uncensored case, though the censored case
was dierent.
A second, smaller data set exhibiting PVRwith a 48week treatment periodwas also used; the fit is shown
in Figure 5. While themodel fit appears adequate, the fit value for the parameter δwas around 77.6, which is
two orders of magnitude larger than the typical value. Further inspection reveals that several parameter sets,
many containing unrealistic estimates, can fit this data well. We will discuss this degenerate behavior in the
next section.
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Figure 4.Model fits to (a) the partial viral response data and (b) the relapse data. The vertical dotted line corresponds to the
end of treatment.
Parameter PVR fit (32 weeks) Relapse fit
β (4.168 ± 4.118) × 10−9 8.700 × 10−9
δ 0.1211 ± 0.0586 0.1115
p 25.1 25.1
c 2.702 ± 1.950 2.372
r 5.620 × 10−3 5.620 × 10−3
ϵ 0.6138 ± 0.4457 0.8525
ρ 0.1222 ± 1.1648 0.5
k 0.0238 0.0238
Table 2. Optimized parameters for the PVR (32 weeks treatment) and Relapse data sets. Bold values are those chosen by subset
selection and subsequently estimated. For the PVR data, 95% confidence intervals are included.
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Figure 5.Model fit to partial viral response data with 48 weeks treatment.
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4 Discussion
Our application of sensitivity and identifiability analysis to the Snoeckmodel yields several insights. Over the
chosen parameter distribution, the drug decay constant k and regeneration rate constant r aremuch less sen-
sitive than the other parameters. In the context of HCV treatment, this result suggests that liver regeneration
may be less responsible for dierences in viral load between patients. Further study could focus specifically
on whether the regeneration rate r is significantly associated with dierent patient outcomes.
The parameter subsets chosen provided reasonably good fits to data in the first two cases we presented.
Nevertheless, Figure 4 (b) suggests that using three parametersmay not be adequate. Futurework should sys-
tematically evaluate the eects of subset selection on parameter estimation. In particular, fixing parameters
deemed locally unidentifiable may compromise the power of the model to fit certain data sets.
Due to the small number of observations, confidence intervals for the parameters in Table 2 are all wide
relative to the size of the estimated parameters. However, if we allow the parameter p to vary and repeat the
estimation, the problemworsens.When p is estimated, the estimates themselves change little (less than 6%),
but confidence intervals all become wider. Relative to the previous intervals, the width of the interval on δ
becomes twice as large and that of c is inflated 60-fold. Based on the subset selection results one might have
tried estimatingboth p and c, but examining the confidence intervalsmakes it clear thatmeaningful inference
can only be made about one parameter.
One caveat of this methodology is that global identifiability issues may be missed. Fitting the model to
the data set of Figure 5 yielded many parameter sets with very similar squared errors. Table 3 illustrates
the closeness of fit between parameter sets far away from one another, which heuristically suggests global
unidentifiability. Such behavior implies that the least squares fit is highly sensitive to themeasurement error,
which makes the parameters practically unidentifiable.
Parameter Fit 1 Fit 2 Fit 3
β 1.588 × 10−7 1.183 × 10−7 2.811 × 10−5
δ 90.89 78.57 0.0468
p 25.1 25.1 25.1
c 0.1058 0.1083 195.6
r 5.620 × 10−3 5.620 × 10−3 5.620 × 10−3
ϵ 0.5398 0.6274 0.7320
ρ 0.4082 0.1797 0.9947
k 0.0238 0.0238 0.0238
SSE: 0.246 0.257 0.273
Table 3. Three parameter sets from fitting to the PVR data with 48 weeks treatment. Unidentifiability is suggested by the
closeness in the sum of squared errors (SSE) objective. Estimated parameters are in bold.
There has been some discussion in the literature regarding the value of the constant r. Dahari, Lo, Ribeiro
and Perelson [6] derived a model that is very similar to the model by Snoeck et al. [21], which included
the extra terms involving the parameter r but did not include the non-infectious virion variable VNI . They
obtained values of r = 0.45, 0.54, 0.73 day−1 when fitting their model to biphasic, triphasic and partial viral
decays respectively (see [6, Figure 5]). Snoeck et al. [21] used a value of r = 0.00562 day−1 which was based
on simulations for 51 liver graft donors. Clearly there is a big dierence between these values.
This discrepancy was discussed by Dahari, Lo, Ribeiro and Perelson in [7]. They refitted the liver regen-
eration data and obtained values of r = 0.24, 0.052 day−1. Clearly the second value has moved closer to the
value used in [21], but is still an order of magnitude larger. However, we have shown that r is the least sen-
sitive of all the model parameters when fitting to censored data (Figure 2 (b)) and is also very insensitive
when fitting to uncensored data (Figure 2 (a)). This shows that the value of r has little influence on the fitting
process, which explains why similar models can both fit data with widely varying values of r.
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Figure 6.Model output using the original (solid) and modified (dotted) Snoeck model for (a) the partial viral response case
and (b) the relapse case.
The lifecycle of a single hepatitis C virion ends upon infecting a new hepatocyte [12]. Thus, it was
suggested to the authors that the model equation for dVIdt should include a negative term proportional to
the concentrations of healthy cells and infectious virions. Taking into account this consideration yields the
following modified equation in the Snoeck model:
dVI
dt = (1 − ρ̄)(1 − ϵ̄)pI − cVI − βVIT.
Model output in the original and modified Snoeck models is shown in Figure 6 using the same parameter
sets as the fits in Figure 4. In both cases the viral load drops slightly lower in the modified model. Otherwise,
the results are almost identical. Similarly, the sensitivity functions evaluated using these two parameter sets
were found to be only slightly dierent in the modified Snoeck model. We stress that our focus is on inverse
problem methodologies more so than modeling issues, and at any rate our subset selection results would
likely not be aected by the additional term in the model.
5 Conclusions
This work illustrates the use of several techniques useful in inverse problems. We use global sensitivity
analysis, a sensitivity-based identifiability analysis, and a simple algorithm to choose subsets of parameters
to estimate. These techniques were applied to a recent model for intra-patient HCV dynamics, and we found
that not all parameters estimated in the original study were sensitive and identifiable. Furthermore, we stress
that methods presented would be useful for parameter estimation in a wide variety of dynamical models,
especially those in the form of nonlinear ODEs. More widespread application of sensitivity and identifiability
techniques in these models should lead to more accurate inferences about the model parameters and thus
models which are more relevant to the clinical setting.
Our results pertain to HCV patients undergoing a treatment of interferon-α (IFN) and ribavirin. Recently,
a number of direct-acting antivirals (DAAs) have been developed which significantly improve patient out-
comes [15, 17]. The reader is referred to [5] for a review of some recent models pertaining to treatment
with DAAs.
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